Nature Search

Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial

Niall C Tebbutt
Timothy J Price
Val Gebski
ResearchOpen Access11 Feb 2016
British Journal of Cancer

Volume: 114, P: 505-509
Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial

N C Tebbutt
M M Parry
V J Gebski
ResearchOpen Access14 Feb 2013
British Journal of Cancer

Volume: 108, P: 771-774
Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study

David K. Lau
Rebecca Y. Tay
Niall C. Tebbutt
Research12 Mar 2018
British Journal of Cancer

Volume: 118, P: 966-971
Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice

Niall C. Tebbutt
Andrew S. Giraud
Matthias Ernst
Research09 Sept 2002
Nature Medicine

Volume: 8, P: 1089-1097
VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer

Fiona Chionh
Val Gebski
Niall C. Tebbutt
ResearchOpen Access24 Jan 2022
Scientific Reports

Volume: 12, P: 1-14
GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

An analysis of 24,202 critical cases of COVID-19 identifies potentially druggable targets in inflammatory signalling (JAK1), monocyte–macrophage activation and endothelial permeability (PDE4A), immunometabolism (SLC2A5 and AK5), and host factors required for viral entry and replication (TMPRSS2 and RAB2A).

Erola Pairo-Castineira
Konrad Rawlik
J. Kenneth Baillie
ResearchOpen Access17 May 2023
Nature

Volume: 617, P: 764-768
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer

A J Weickhardt
D S Williams
N C Tebbutt
ResearchOpen Access30 Jun 2015
British Journal of Cancer

Volume: 113, P: 37-45
RHOA inactivation enhances Wnt signalling and promotes colorectal cancer

The small GTPase RhoA has oncogenic effects in several cancer types. Here the authors show that loss of RhoA accelerates colon cancer progression by promoting accumulation of nuclear ß-catenin, resulting in enhanced proliferation and invasion mediated by the Wnt signalling pathway in human and murine colon cancer cells.

Paulo Rodrigues
Irati Macaya
Diego Arango
Research21 Nov 2014
Nature Communications

Volume: 5, P: 1-15
Mapping the human genetic architecture of COVID-19

A global network of researchers was formed to investigate the role of human genetics in SARS-CoV-2 infection and COVID-19 severity; this paper reports 13 genome-wide significant loci and potentially actionable mechanisms in response to infection.

Mari E. K. Niemi
Juha Karjalainen
Chloe Donohue
ResearchOpen Access08 Jul 2021
Nature

Volume: 600, P: 472-477
Whole-genome sequencing reveals host factors underlying critical COVID-19

Whole-genome sequencing, transcriptome-wide association and fine-mapping analyses in over 7,000 individuals with critical COVID-19 are used to identify 16 independent variants that are associated with severe illness in COVID-19.

Athanasios Kousathanas
Erola Pairo-Castineira
J. Kenneth Baillie
ResearchOpen Access07 Mar 2022
Nature

Volume: 607, P: 97-103
Model systems and unique biological features of high and low-grade colorectal cancer (CRC) revealed by xenografting 84 human CRC cell lines

Colorectal cancer cell lines accurately recapitulate the histological and transcriptional properties of low-grade and high-grade colorectal cancers.

Ian Y. Luk
Jennifer K. Mooi
John M. Mariadason
ResearchOpen Access05 Jun 2025
Communications Biology

Volume: 8, P: 1-13
A second update on mapping the human genetic architecture of COVID-19

Masahiro Kanai
Shea J. Andrews
Matthew Solomonson
ResearchOpen Access06 Sept 2023
Nature

Volume: 621, P: E7-E26
Targeting the ERBB family in cancer: couples therapy

Many therapeutic agents target the ERBB family of receptor tyrosine kinases in various cancers. This Opinion article describes our latest understanding of the value of combining inhibitors directed towards an individual ERBB family member, including the molecular mechanisms of synergy and progress in clinical trials.

Niall Tebbutt
Mikkel W. Pedersen
Terrance G. Johns
Reviews16 Aug 2013
Nature Reviews Cancer

Volume: 13, P: 663-673
Author Correction: DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis

Lars Tögel
Rebecca Nightingale
John M. Mariadason
Amendments and CorrectionsOpen Access10 Feb 2023
Scientific Reports

Volume: 13, P: 1-2
BCL-X_L inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF^V600E colorectal cancer

Laura J. Jenkins
Ian Y. Luk
John M. Mariadason
ResearchOpen Access01 Mar 2024
Cell Death & Disease

Volume: 15, P: 1-9
Author Correction: GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

Erola Pairo-Castineira
Konrad Rawlik
J. Kenneth Baillie
Amendments and CorrectionsOpen Access11 Jul 2023
Nature

Volume: 619, P: E61
Epithelial de-differentiation triggered by co-ordinate epigenetic inactivation of the EHF and CDX1 transcription factors drives colorectal cancer progression

Ian Y. Luk
Laura J. Jenkins
John M. Mariadason
ResearchOpen Access23 May 2022
Cell Death & Differentiation

Volume: 29, P: 2288-2302
Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer

David S. Williams
Dmitri Mouradov
Oliver M. Sieber
Research30 Aug 2019
Modern Pathology

Volume: 33, P: 483-495
DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis

Lars Tögel
Rebecca Nightingale
John M. Mariadason
ResearchOpen Access29 Jan 2018
Scientific Reports

Volume: 8, P: 1-11
Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

N C Tebbutt
M M Cummins
J Zalcberg
ResearchOpen Access12 Jan 2010
British Journal of Cancer

Volume: 102, P: 475-481
Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis

D Damianovich
M Adena
N C Tebbutt
ResearchOpen Access06 Feb 2007
British Journal of Cancer

Volume: 96, P: 546-550
The prognostic impact of peritoneal tumour DNA in gastrointestinal and gynaecological malignancies: a systematic review

Zexi Allan
Sasha Witts
David S. Liu
Reviews12 Sept 2023
British Journal of Cancer

Volume: 129, P: 1717-1726

Search

Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial

Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study

Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer

GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer

RHOA inactivation enhances Wnt signalling and promotes colorectal cancer

Mapping the human genetic architecture of COVID-19

Whole-genome sequencing reveals host factors underlying critical COVID-19

Model systems and unique biological features of high and low-grade colorectal cancer (CRC) revealed by xenografting 84 human CRC cell lines

A second update on mapping the human genetic architecture of COVID-19

Targeting the ERBB family in cancer: couples therapy

Author Correction: DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis

BCL-X_L inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF^V600E colorectal cancer

Author Correction: GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

Epithelial de-differentiation triggered by co-ordinate epigenetic inactivation of the EHF and CDX1 transcription factors drives colorectal cancer progression

Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer

DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis

The prognostic impact of peritoneal tumour DNA in gastrointestinal and gynaecological malignancies: a systematic review

Search

Quick links

Search

Filter By:

Search

Quick links